Manfred Ogris

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4586596/publications.pdf Version: 2024-02-01



MANEDED OCDIS

#	Article	IF	CITATIONS
1	Endothelial Retargeting of AAV9 In Vivo. Advanced Science, 2022, 9, e2103867.	5.6	17
2	Investigating 3R In Vivo Approaches for Bioâ€Distribution and Efficacy Evaluation of Nucleic Acid Nanocarriers: Studies on Peptideâ€Mimicking Ionizable Lipid. Small, 2022, , 2107768.	5.2	1
3	Structure-based peptide ligand design for improved epidermal growth factor receptor targeted gene delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 176, 211-221.	2.0	2
4	Surface Modification of E. coli Outer Membrane Vesicles with Glycosylphosphatidylinositol-Anchored Proteins: Generating Pro/Eukaryote Chimera Constructs. Membranes, 2021, 11, 428.	1.4	2
5	CD47-targeted cancer immunogene therapy: Secreted SIRPα-Fc fusion protein eradicates tumors by macrophage and NK cell activation. Molecular Therapy - Oncolytics, 2021, 23, 192-204.	2.0	12
6	Combined Chemisorption and Complexation Generate siRNA Nanocarriers with Biophysics Optimized for Efficient Gene Knockdown and Air–Blood Barrier Crossing. ACS Applied Materials & Interfaces, 2020, 12, 30095-30111.	4.0	7
7	Correlated Multimodal Imaging in Life Sciences: Expanding the Biomedical Horizon. Frontiers in Physics, 2020, 8, .	1.0	61
8	Mechanistic profiling of the release kinetics of siRNA from lipidoid-polymer hybrid nanoparticles in vitro and in vivo after pulmonary administration. Journal of Controlled Release, 2019, 310, 82-93.	4.8	33
9	Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis. Cancer Cell, 2019, 35, 798-815.e5.	7.7	212
10	Firefly Luciferase-Based Reporter Gene Assay for Investigating Nanoparticle-Mediated Nucleic Acid Delivery. Methods in Molecular Biology, 2019, 1943, 227-239.	0.4	5
11	Synthesis of Polyethylenimine-Based Nanocarriers for Systemic Tumor Targeting of Nucleic Acids. Methods in Molecular Biology, 2019, 1943, 83-99.	0.4	7
12	Peptide-Targeted Polyplexes for Aerosol-Mediated Gene Delivery to CD49f-Overexpressing Tumor Lesions in Lung. Molecular Therapy - Nucleic Acids, 2019, 18, 774-786.	2.3	14
13	Luminescent and fluorescent triple reporter plasmid constructs for Wnt, Hedgehog and Notch pathway. PLoS ONE, 2019, 14, e0226570.	1.1	7
14	Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis. Oncolmmunology, 2018, 7, e1424676.	2.1	35
15	Novel PAMAM-PEG-Peptide Conjugates for siRNA Delivery Targeted to the Transferrin and Epidermal Growth Factor Receptors. Journal of Personalized Medicine, 2018, 8, 4.	1.1	17
16	In vivo tracking of adipose tissue grafts with cadmium-telluride quantum dots. Archives of Plastic Surgery, 2018, 45, 111-117.	0.4	0
17	Fluorescence- and computed tomography for assessing the biodistribution of siRNA after intratracheal application in mice. International Journal of Pharmaceutics, 2017, 525, 359-366.	2.6	12
18	Systemic tumorâ€ŧargeted sodium iodide symporter (NIS) gene therapy of hepatocellular carcinoma mediated by B6 peptide polyplexes. Journal of Gene Medicine, 2017, 19, e2957.	1.4	20

#	Article	IF	CITATIONS
19	Reintroducing the Sodium–lodide Symporter to Anaplastic Thyroid Carcinoma. Thyroid, 2017, 27, 1534-1543.	2.4	21
20	Multimodal Fluorescence and Bioluminescence Imaging Reveals Transfection Potential of Intratracheally Administered Polyplexes for Breast Cancer Lung Metastases. Human Gene Therapy, 2017, 28, 1202-1213.	1.4	12
21	Cadmium Telluride Quantum Dots as a Fluorescence Marker for Adipose Tissue Grafts. Annals of Plastic Surgery, 2017, 78, 217-222.	0.5	2
22	Amorphous Silica Particles Relevant in Food Industry Influence Cellular Growth and Associated Signaling Pathways in Human Gastric Carcinoma Cells. Nanomaterials, 2017, 7, 18.	1.9	14
23	Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene. Oncotarget, 2017, 8, 33393-33404.	0.8	33
24	Transient Hepatic Overexpression of Insulin-Like Growth Factor 2 Induces Free Cholesterol and Lipid Droplet Formation. Frontiers in Physiology, 2016, 7, 147.	1.3	19
25	Biopharmaceuticals and gene vectors opening new avenues in cancer immune therapy. Therapeutic Delivery, 2016, 7, 419-422.	1.2	3
26	Up-Scaled Synthesis and Characterization of Nonviral Gene Delivery Particles for TransientIn VitroandIn VivoTransgene Expression. Human Gene Therapy Methods, 2016, 27, 87-97.	2.1	9
27	Evaluation of improved PAMAM-G5 conjugates for gene delivery targeted to the transferrin receptor. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 94, 116-122.	2.0	12
28	Receptor Crosslinking in Drug Delivery: Detour to the Lysosome?. Molecular Therapy, 2015, 23, 1802-1804.	3.7	4
29	Assessment of Raman spectroscopy as a fast and non-invasive method for total stratum corneum thickness determination of pig skin. International Journal of Pharmaceutics, 2015, 495, 482-484.	2.6	24
30	Simultaneous determination of active component and vehicle penetration from F-DPPC liposomes into porcine skin layers. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 97, 90-95.	2.0	11
31	Gene therapy and imaging in preclinical and clinical oncology: recent developments in therapy and therapy theranostics. Therapeutic Delivery, 2014, 5, 1275-1296.	1.2	13
32	The stem cell factor SOX2 regulates the tumorigenic potential in human gastric cancer cells. Carcinogenesis, 2014, 35, 942-950.	1.3	84
33	Generation of a tumor- and tissue-specific episomal non-viral vector system. BMC Biotechnology, 2013, 13, 49.	1.7	15
34	Adenoviral Vectors Coated with PAMAM Dendrimer Conjugates Allow CAR Independent Virus Uptake and Targeting to the EGF Receptor. Molecular Pharmaceutics, 2013, 10, 606-618.	2.3	40
35	Synthesis of Polyethylenimine-Based Nanocarriers for Systemic Tumor Targeting of Nucleic Acids. , 2013, 948, 105-120.		12
36	Systemic TNFα Gene Therapy Synergizes With Liposomal Doxorubicine in the Treatment of Metastatic Cancer. Molecular Therapy, 2013, 21, 300-308.	3.7	42

#	Article	IF	CITATIONS
37	Targeted therapy of cancer stem cells: science or fiction. Therapeutic Delivery, 2013, 4, 135-138.	1.2	О
38	Gene Therapy for Advanced Melanoma: Selective Targeting and Therapeutic Nucleic Acids. Journal of Drug Delivery, 2013, 2013, 1-15.	2.5	18
39	Gene therapy in the clinics: shifting into the next gear. Therapeutic Delivery, 2013, 4, 1359-1363.	1.2	1
40	Systemic Image-Guided Liver Cancer Radiovirotherapy Using Dendrimer-Coated Adenovirus Encoding the Sodium Iodide Symporter as Theranostic Gene. Journal of Nuclear Medicine, 2013, 54, 1450-1457.	2.8	64
41	EGFR-Targeted Adenovirus Dendrimer Coating for Improved Systemic Delivery of the Theranostic NIS Gene. Molecular Therapy - Nucleic Acids, 2013, 2, e131.	2.3	54
42	De-targeting by miR-143 decreases unwanted transgene expression in non-tumorigenic cells. Gene Therapy, 2013, 20, 1104-1109.	2.3	12
43	Nucleic Acid Carrier Systems Based on Polyethylenimine Conjugates for the Treatment of Metastatic Tumors. Current Medicinal Chemistry, 2013, 20, 3456-3470.	1.2	4
44	Synthesis of Linear Polyethylenimine and Use in Transfection. Cold Spring Harbor Protocols, 2012, 2012, 2012, pdb.prot067868.	0.2	4
45	In Vivo Imaging Enables High Resolution Preclinical Trials on Patients' Leukemia Cells Growing in Mice. PLoS ONE, 2012, 7, e52798.	1.1	39
46	PolyIC GE11 polyplex inhibits EGFRâ€overexpressing tumors. IUBMB Life, 2012, 64, 324-330.	1.5	47
47	Tuning Nanoparticle Uptake: Live-Cell Imaging Reveals Two Distinct Endocytosis Mechanisms Mediated by Natural and Artificial EGFR Targeting Ligand. Nano Letters, 2012, 12, 3417-3423.	4.5	111
48	Liposome based systems for systemic siRNA delivery: Stability in blood sets the requirements for optimal carrier design. Journal of Controlled Release, 2012, 158, 362-370.	4.8	175
49	Highly Sensitive Bioluminescence in Vivo Imaging Enables Individualized Preclinical Treatment Trials On Patients ALL Tumor Cells Growing in Mice Blood, 2012, 120, 2602-2602.	0.6	0
50	Disconnecting the Yin and Yang Relation of Epidermal Growth Factor Receptor (EGFR)-Mediated Delivery: A Fully Synthetic, EGFR-Targeted Gene Transfer System Avoiding Receptor Activation. Human Gene Therapy, 2011, 22, 1463-1473.	1.4	64
51	Image-Guided Tumor-Selective Radioiodine Therapy of Liver Cancer After Systemic Nonviral Delivery of the Sodium Iodide Symporter Gene. Human Gene Therapy, 2011, 22, 1563-1574.	1.4	44
52	To Be Targeted: Is the Magic Bullet Concept a Viable Option for Synthetic Nucleic Acid Therapeutics?. Human Gene Therapy, 2011, 22, 799-807.	1.4	43
53	Epidermal Growth Factor Receptor-targeted 1311-therapy of Liver Cancer Following Systemic Delivery of the Sodium Iodide Symporter Gene. Molecular Therapy, 2011, 19, 676-685.	3.7	99
54	The establishment of an up-scaled micro-mixer method allows the standardized and reproducible preparation of well-defined plasmid/LPEI polyplexes. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 77, 182-185.	2.0	29

#	Article	IF	CITATIONS
55	siRNA therapeutics: chances, pitfalls and future potential. Therapeutic Delivery, 2011, 2, 1101-1104.	1.2	1
56	Development of a lyophilized plasmid/LPEI polyplex formulation with long-term stability—A step closer from promising technology to application. Journal of Controlled Release, 2011, 151, 246-255.	4.8	54
57	Dual-targeted polyplexes: One step towards a synthetic virus for cancer gene therapy. Journal of Controlled Release, 2011, 152, 127-134.	4.8	96
58	Intrinsic phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles. Virology, 2011, 409, 77-83.	1.1	73
59	Poly(I:C)-Mediated Tumor Growth Suppression in EGF-Receptor Overexpressing Tumors Using EGF-Polyethylene Glycol-Linear Polyethylenimine as Carrier. Pharmaceutical Research, 2011, 28, 731-741.	1.7	77
60	Live in vivo imaging of Egr-1 promoter activity during neonatal development, liver regeneration and wound healing. BMC Developmental Biology, 2011, 11, 28.	2.1	17
61	Sustained, high transgene expression in liver with plasmid vectors using optimized promoterâ€enhancer combinations. Journal of Gene Medicine, 2011, 13, 382-391.	1.4	39
62	EGFR-Homing dsRNA Activates Cancer-Targeted Immune Response and Eliminates Disseminated EGFR-Overexpressing Tumors in Mice. Clinical Cancer Research, 2011, 17, 1033-1043.	3.2	30
63	Nucleic Acid-Based Therapeutics for Glioblastoma. Anti-Cancer Agents in Medicinal Chemistry, 2011, 11, 693-699.	0.9	1
64	Cancer gene therapies come of age. Therapeutic Delivery, 2010, 1, 211-214.	1.2	2
65	Controlled removal of a nonviral episomal vector from transfected cells. Gene, 2010, 466, 36-42.	1.0	21
66	Low generation PAMAM dendrimer and CpG free plasmids allow targeted and extended transgene expression in tumors after systemic delivery. Journal of Controlled Release, 2010, 146, 99-105.	4.8	68
67	Improved <i>in vivo</i> gene transfer into tumor tissue by stabilization of pseudodendritic oligoethylenimineâ€based polyplexes. Journal of Gene Medicine, 2010, 12, 180-193.	1.4	24
68	In vivo chemoresistance of prostate cancer in metronomic cyclophosphamide therapy. Journal of Proteomics, 2010, 73, 1342-1354.	1.2	32
69	pEPito: a significantly improved non-viral episomal expression vector for mammalian cells. BMC Biotechnology, 2010, 10, 20.	1.7	66
70	Capsomer-Specific Fluorescent Labeling of Adenoviral Vector Particles Allows for Detailed Analysis of Intracellular Particle Trafficking and the Performance of Bioresponsive Bonds for Vector Capsid Modifications. Human Gene Therapy, 2010, 21, 1155-1167.	1.4	18
71	Clinical Adenoviral Gene Therapy for Prostate Cancer. Human Gene Therapy, 2010, 21, 807-813.	1.4	25
72	Adenovirus-Derived Vectors for Prostate Cancer Gene Therapy. Human Gene Therapy, 2010, 21, 795-805.	1.4	29

#	Article	IF	CITATIONS
73	Nucleic acid therapeutics: concepts for targeted delivery to solid tumors. Therapeutic Delivery, 2010, 1, 91-107.	1.2	8
74	In Vivo Imaging In the Individualized Mouse Model of Acute Lymphoblastic Leukemia Enables Highly Sensitive and Continuous Follow up of Patient-Derived Xenografts. Blood, 2010, 116, 3259-3259.	0.6	0
75	Near-infrared-emitting semiconductor quantum dots for tumor imaging and targeting. Current Opinion in Molecular Therapeutics, 2010, 12, 331-9.	2.8	8
76	Targeted Radioiodine Therapy of Neuroblastoma Tumors following Systemic Nonviral Delivery of the Sodium Iodide Symporter Gene. Clinical Cancer Research, 2009, 15, 6079-6086.	3.2	65
77	Drug Nanocarriers Labeled With Near-infrared-emitting Quantum Dots (Quantoplexes): Imaging Fast Dynamics of Distribution in Living Animals. Molecular Therapy, 2009, 17, 1849-1856.	3.7	87
78	Receptor-Mediated Delivery of Proteins and Peptides to Tumors. , 2009, , 269-295.		1
79	Synthesis and Biological Evaluation of a Bioresponsive and Endosomolytic siRNAâ^'Polymer Conjugate. Molecular Pharmaceutics, 2009, 6, 752-762.	2.3	166
80	An Acid Sensitive Ketal-Based Polyethylene Glycol-Oligoethylenimine Copolymer Mediates Improved Transfection Efficiency at Reduced Toxicity. Pharmaceutical Research, 2008, 25, 2937-2945.	1.7	67
81	Novel degradable oligoethylenimine acrylate ester-based pseudodendrimers for in vitro and in vivo gene transfer. Gene Therapy, 2008, 15, 18-29.	2.3	92
82	Amine-reactive pyridylhydrazone-based PEG reagents for pH-reversible PEI polyplex shielding. European Journal of Pharmaceutical Sciences, 2008, 34, 309-320.	1.9	80
83	Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy?. Journal of Cellular and Molecular Medicine, 2008, 12, 2704-2716.	1.6	9
84	Dynamics of photoinduced endosomal release of polyplexes. Journal of Controlled Release, 2008, 130, 175-182.	4.8	89
85	Polyhydroxyethylaspartamide-spermine copolymers: Efficient vectors for gene delivery. Journal of Controlled Release, 2008, 131, 54-63.	4.8	27
86	Oligoethylenimine-grafted polypropylenimine dendrimers as degradable and biocompatible synthetic vectors for gene delivery. Journal of Controlled Release, 2008, 132, 131-140.	4.8	106
87	Hyperthermia-Induced Targeting of Thermosensitive Gene Carriers to Tumors. Human Gene Therapy, 2008, 19, 1283-1292.	1.4	51
88	Acetal Linked Oligoethylenimines for Use As pH-Sensitive Gene Carriers. Bioconjugate Chemistry, 2008, 19, 1625-1634.	1.8	91
89	Induction of Apoptosis in Murine Neuroblastoma by Systemic Delivery of Transferrin-Shielded siRNA Polyplexes for Downregulation of Ran. Oligonucleotides, 2008, 18, 161-174.	2.7	55
90	MR Characterization of Mild Hyperthermia-Induced Gadodiamide Release From Thermosensitive Liposomes in Solid Tumors. Investigative Radiology, 2008, 43, 877-892.	3.5	39

#	Article	IF	CITATIONS
91	Hyperthermia induced targeting of thermosensitive gene carriers to tumors. Human Gene Therapy, 2008, 19, 081015093227032.	1.4	17
92	Cellular Dynamics of EGF Receptor–Targeted Synthetic Viruses. Molecular Therapy, 2007, 15, 1297-1305.	3.7	159
93	Corrigendum to "Cellular Dynamics of EGF Receptor–targeted Synthetic Viruses― Molecular Therapy, 2007, 15, 1735.	3.7	0
94	A dimethylmaleic acid–melittinâ€polylysine conjugate with reduced toxicity, pHâ€ŧriggered endosomolytic activity and enhanced gene transfer potential. Journal of Gene Medicine, 2007, 9, 797-805.	1.4	83
95	Electrophoretic purification of tumor-targeted polyethylenimine-based polyplexes reduces toxic side effects in vivo. Journal of Controlled Release, 2007, 122, 236-245.	4.8	57
96	Novel Biocompatible Cationic Copolymers Based on Polyaspartylhydrazide Being Potent as Gene Vector on Tumor Cells. Pharmaceutical Research, 2007, 24, 2213-2222.	1.7	10
97	Temperature Dependent Gene Expression Induced by PNIPAM-Based Copolymers:  Potential of Hyperthermia in Gene Transfer. Bioconjugate Chemistry, 2006, 17, 766-772.	1.8	92
98	Gene Carriers Based on Hexanediol Diacrylate Linked Oligoethylenimine:  Effect of Chemical Structure of Polymer on Biological Properties. Bioconjugate Chemistry, 2006, 17, 1339-1345.	1.8	76
99	Transferrin Receptor Mediated Delivery of Protein and Peptide Drugs into Tumors. , 2006, , 205-223.		0
100	Effects of hypoxia and limited diffusion in tumor cell microenvironment on bystander effect of P450 prodrug therapy. Cancer Gene Therapy, 2006, 13, 771-779.	2.2	9
101	Degradable gene carriers based on oligomerized polyamines. European Journal of Pharmaceutical Sciences, 2006, 29, 414-425.	1.9	94
102	Melittin analogs with high lytic activity at endosomal pH enhance transfection with purified targeted PEI polyplexes. Journal of Controlled Release, 2006, 112, 240-248.	4.8	127
103	DNA polyplexes based on degradable oligoethylenimine-derivatives: Combination with EGF receptor targeting and endosomal release functions. Journal of Controlled Release, 2006, 116, 115-122.	4.8	40
104	Reversibly stable thiopolyplexes for intracellular delivery of genes. Journal of Controlled Release, 2006, 115, 322-334.	4.8	55
105	The Transport of Nanosized Gene Carriers Unraveled by Live-Cell Imaging. Angewandte Chemie - International Edition, 2006, 45, 1568-1572.	7.2	123
106	Nucleic Acid Based Therapeutics for Tumor Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2006, 6, 563-570.	0.9	7
107	The Internalization Route Resulting in Successful Gene Expression Depends on both Cell Line and Polyethylenimine Polyplex Type. Molecular Therapy, 2006, 14, 745-753.	3.7	289
108	C- versus N-terminally linked melittin-polyethylenimine conjugates: the site of linkage strongly influences activity of DNA polyplexes. Journal of Gene Medicine, 2005, 7, 1335-1347.	1.4	58

#	Article	IF	CITATIONS
109	EGF Receptor-Targeted Synthetic Double-Stranded RNA Eliminates Glioblastoma, Breast Cancer, and Adenocarcinoma Tumors in Mice. PLoS Medicine, 2005, 3, e6.	3.9	90
110	Specific Targets in Tumor Tissue for the Delivery of Therapeutic Genes. Anti-Cancer Agents in Medicinal Chemistry, 2005, 5, 157-171.	7.0	35
111	Cryoconserved shielded and EGF receptor targeted DNA polyplexes: cellular mechanisms. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 60, 279-285.	2.0	28
112	Toward Synthetic Viruses: Endosomal pH-Triggered Deshielding of Targeted Polyplexes Greatly Enhances Gene Transfer in vitro and in vivo. Molecular Therapy, 2005, 11, 418-425.	3.7	310
113	Functional Analysis of Genomic DNA, cDNA, and Nucleotide Sequence of the Mature C-Type Natriuretic Peptide Gene in Vascular Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1646-1651.	1.1	16
114	Stabilized Nonviral Formulations for the Delivery of MCP-1 Gene into Cells of the Vasculoendothelial System. Pharmaceutical Research, 2004, 21, 683-691.	1.7	17
115	Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer. Journal of Gene Medicine, 2004, 6, 1102-1111.	1.4	417
116	Stability and release characteristics of poly(d,l-lactide-co-glycolide) encapsulated CaPi-DNA coprecipitation. International Journal of Pharmaceutics, 2004, 269, 61-70.	2.6	27
117	Non-viral cancer gene therapy – what is best? ◾. Drug Discovery Today, 2003, 8, 63.	3.2	2
118	Tumor-targeted gene therapy: strategies for the preparation of ligand–polyethylene glycol–polyethylenimine/DNA complexes. Journal of Controlled Release, 2003, 91, 173-181.	4.8	265
119	Failure to generate atheroprotective apolipoprotein AI phenotypes using synthetic RNA/DNA oligonucleotides (chimeraplasts). Journal of Gene Medicine, 2003, 5, 795-802.	1.4	20
120	Nanoparticles bearing polyethyleneglycol-coupled transferrin as gene carriers: preparation and in vitro evaluation. International Journal of Pharmaceutics, 2003, 259, 93-101.	2.6	88
121	Tissue-dependent factors affect gene delivery to tumors in vivo. Gene Therapy, 2003, 10, 1079-1088.	2.3	47
122	Novel Shielded Transferrinâ^'Polyethylene Glycolâ^'Polyethylenimine/DNA Complexes for Systemic Tumor-Targeted Gene Transfer. Bioconjugate Chemistry, 2003, 14, 222-231.	1.8	295
123	Importance of Lateral and Steric Stabilization of Polyelectrolyte Gene Delivery Vectors for Extended Systemic Circulation. Molecular Therapy, 2002, 5, 463-472.	3.7	273
124	Development of Long-circulating Polyelectrolyte Complexes for Systemic Delivery of Genes. Journal of Drug Targeting, 2002, 10, 93-98.	2.1	47
125	Tumor-targeted gene transfer with DNA polyplexes. Somatic Cell and Molecular Genetics, 2002, 27, 85-95.	0.7	54
126	Targeting tumors with non-viral gene delivery systems. Drug Discovery Today, 2002, 7, 479-485.	3.2	153

#	Article	IF	CITATIONS
127	Transmembrane Targeting of DNA with Membrane Active Peptides. , 2002, , 441-458.		2
128	DNA/polyethylenimine transfection particles: Influence of ligands, polymer size, and PEGylation on internalization and gene expression. AAPS PharmSci, 2001, 3, 43-53.	1.3	178
129	Adenovirus Hexon Protein Enhances Nuclear Delivery and Increases Transgene Expression of Polyethylenimine/Plasmid DNA Vectors. Molecular Therapy, 2001, 4, 473-483.	3.7	69
130	Melittin Enables Efficient Vesicular Escape and Enhanced Nuclear Access of Nonviral Gene Delivery Vectors. Journal of Biological Chemistry, 2001, 276, 47550-47555.	1.6	200
131	Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells. Nucleic Acids Research, 2001, 29, 3882-3891.	6.5	192
132	PEGylated DNA/transferrin–PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Therapy, 1999, 6, 595-605.	2.3	1,168
133	Polycation-based DNA complexes for tumor-targeted gene deliveryin vivo. Journal of Gene Medicine, 1999, 1, 111-120.	1.4	406
134	Differential behaviour of lipid based and polycation based gene transfer systems in transfecting primary human fibroblasts: a potential role of polylysine in nuclear transport. Biochimica Et Biophysica Acta - General Subjects, 1999, 1428, 57-67.	1.1	55
135	Polycation-based DNA complexes for tumor-targeted gene delivery in vivo. , 1999, 1, 111.		3
136	Influence of the DNA complexation medium on the transfection efficiency of lipospermine/DNA particles. Gene Therapy, 1998, 5, 855-860.	2.3	43
137	The size of DNA/transferrin-PEI complexes is an important factor for gene expression in cultured cells. Gene Therapy, 1998, 5, 1425-1433.	2.3	562
138	Polylysine-based transfection systems utilizing receptor-mediated delivery. Advanced Drug Delivery Reviews, 1998, 30, 97-113.	6.6	487
139	Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery. Gene Therapy, 1997, 4, 409-418.	2.3	358
140	Stabilization of gene delivery systems by freeze-drying. International Journal of Pharmaceutics, 1997, 157, 233-238.	2.6	75